

Suppl. Table 1. Comparison of CNSL cases to peripheral PTLD controls. For age Wilcoxon signed-rank test was used because distribution was non-normal. For sex and age, Fisher exact test was used.


	CNSL (n=12)	Peripheral PTLD (n=24)	p-value
	Mean±SD	Mean±SD	
Age	54.6±19)	54.1±15	0.907
	n= (%)	n= (%)	
Sex			
Female	0 (0)	7 (29)	0.070
Male	12 (100)	17 (71)	
Race			
White	10 (83)	23 (96)	0.253
Indian	1 (8)	0 (0)	
Black	1 (8)	0 (0)	
Multiple	0 (0)	1 (4)	

Suppl. Table 2. Oligonucleotide primers and guideRNA. *phosphorothioate-modified oligo


Primer ID	Forward	Reverse	Comment/details
qRT-PCR primers (RNA expression analysis)			
BXLF1	GCATAGTAGTCTTCCCCACACC	TCC AAT TGT GAC CCA CCT AAC	Hydrolysis probe: /56FAM/AG GGA ACA G/ZEN/G CAG GTT TGA TTA CTG G/3IABkFQ/
BGLF4	CCCATGGTGTCTGTGAAT	GGCCTCAAAGATGCCGTTA	Hydrolysis probe: /56-FAM/TA ATG TCC G/ZEN/A ATG GAA GAG GCC GC/3IABkFQ/
LMP1	TGTCGTGCAAATCCAGAG	ACTTGGAGCCCTTGTATACTC	Hydrolysis probe: /56-FAM/ATCACCTCCTGCTCATCGCTC/3IABkFQ/
BZLF1	GTTGCTAACTGGCCCG	ACCACAACAGCCAGAACATCG	Hydrolysis probe: /56-FAM/TCTAGTTCAGAACATCGCATTCCAGC/3IABkFQ/ (IDT ref. Hs.PT.39a.22214847)
ACTB	(see IDT ref. Hs.PT.39a.22214847)	(see IDT ref. Hs.PT.39a.22214847)	(IDT ref. Hs.PT.39a.22214847)
qPCR primers (EBV load determination)			
EBNA1	TCATCATCGGGTCTCC	CCTACAGGGTGGAAAATGGC	
ACTB	CAGGAGCTCGTAGCTCTC	TCGTGCGTACATTAAGGAG	
TET2 guideRNA and homology templates.			
TET2 gRNA	CAGGACTCACACGACTATT	CTACTTCTGTGAAAGTCAGGACTCA	
TET2 TrueTag template*	TATTATGGAATACCTCTATGAAAGGA AGCCAGAACATGGAGTGGCTCAGGTT TGGA	CACGACTCTGGCGATGCATACAGAG	
Luciferase reporter assay primers. Entries correspond to reporters shown in Fig. 3A, top to bottom, with all forward primers carrying 5'-AAGCTT(HindIII) and all reverse primers 5'-CCTGCAGG(SbfI)			
BGLF4_LUCIA_F1R4	GTTCTCAAATGGCTGAGG	CCCCCGTTTACAGAAGAAT	ChrEBV:111327-112388
BGLF4_LUCIA_F1R3	GTTCTCAAATGGCTGAGG	GCGGTTTATACACCATGTGC	ChrEBV:111327-112063
BGLF4_LUCIA_F1R2	GTTCTCAAATGGCTGAGG	GGAAGCCTCCACTGGAACTA	ChrEBV:111327-111740
BGLF4_LUCIA_F4R4	TGGTGTATAAACCCGAGTGG	CCCCCGTTTACAGAAGAAT	ChrEBV:112049-112388
BGLF4_LUCIA_F3R4	GGAGGCTTCCCGGATATT	CCCCCGTTTACAGAAGAAT	ChrEBV:111731-112388
BGLF4_LUCIA_F1R1	GTTCTCAAATGGCTGAGG	TTGAAACACAGTTACATCTGCTC	ChrEBV:111327-111555
BGLF4_LUCIA_F2R4	CCGAGCAGATGTAACGTGTT	CCCCCGTTTACAGAAGAAT	ChrEBV:111531-112388
BGLF4_LUCIA_F2R3	CCGAGCAGATGTAACGTGTT	GCGGTTTATACACCATGTGC	ChrEBV:111531-112063
BGLF4_LUCIA_F2R2	CCGAGCAGATGTAACGTGTT	GGAAGCCTCCACTGGAACTA	ChrEBV:111531-111740
BGLF4_LUCIA_F3R3	GGAGGCTTCCCGGATATT	GCGGTTTATACACCATGTGC	ChrEBV:111731-112063
5'RACE primers			
5'RACE_Qt	CCAGTGAGCAGAGTGA	GAGGACTCGAGCTAAG	
5'RACE_Qo	CCAGTGAGCAGAGTGA	GAGGACTCGAGCTAAG	
5'RACE_Qi	GAGGACTCGAGCTAAG		
BGLF4_GSP_RT1	CTCAACTCCGCAGGCCATATT		
BGLF4_GSP_RT2	GTGGCGCAGGGACTCTAAG		
BGLF4_GSP1	CACATCATGTTCTCAAATG		
BGLF4_GSP2	CCCGAGCAGATGTAACGTGTT		
BGLF4_GSP3	CTGTCGAGCTCGTCT		
BGLF4_GSP4	GGTTCAAACAGAGCGTGGTC		
EpiTYPER methylation analysis primers. All forward primers carry 5'tag AGGAAGAGAG, all reverse primers carry 5'tag CAGTAATACGACTCACTATAGGGAGAAGCT			
BGLF4_1	AGGGGTTTGGGGAGATTTA	CCAAAAATCAACTACAAACAACAAAAA	ChrEBV:111246-111429
BGLF4_2	GGTGATTATTTGATAGGTAGAAA	TCTAATAACCCAAACAACTAAAAACCTC	ChrEBV:111448-111640
BGLF4_3	GTGTGTTTTTTGTTGTTGTT	CTCATCTTATAATCACCATATCC	ChrEBV:111656-111876
BGLF4_4	GTGATGAAAAGGTTTGTGAGGA	CATTCTAACACACCTCCACAAATA	ChrEBV:111879-112032
BZLF1	GGTTGATTGGTTTTATTAGGG	ACCCCTACCTCCTCTTAACCT	ChrEBV:91358-91520
BXLFI	GTTGTGATTGTGTTATTGTTT	TTTAAACCAAAACTAAAACCTACACT	ChrEBV:132930-133073
LMP1	GGTGGTTAAGTGAATAGGAAATGG	ATTACCCACACCTTACCTCACCTA	ChrEBV:169258-169471
LINE1	TTTATTTGTTGATTTGTTAG	TTTATCACCACCAACCTCACCT	
Alu-e	GTTGTAATTAGTTAGTTGGGAGG	CCTACCTAACCTCCCRAATAA	
LTR1	TAAGGTAGAGGGTTAATTGAGTTG	AAATAAAAAAATTCCTTATCCCC	
Methylation iPLEX primers. All forward and reverse primers carry 5'tag ACGTTGGATG. Lowercase bases: oligo mass tags, non-EBV sequence			
BHRF1	GAGTTGTTTAGGTTGTG	CCACAACCCCAACCGTAA	multiplex PCR 1, ext. oligo: cTAGGTTGTGTTGTTGTTG
BMRF1	TTATCGAGGTTCTGTTGAGAG	CCCCAAATACGATCGACC	multiplex PCR 1, ext. oligo: GGTTATTTGGTGGATGTG
BORF1	TATAGCGGAGCTTATGAGG	AAACACAACCCGGCGATT	multiplex PCR 1, ext. oligo: ccTTATGAAGGTTAGGGTT
BVRF1	CGGGAAATTAAATTAGTGGG	CCCTCTAACACTAAACAAAC	multiplex PCR 1, ext. oligo: ttGGATTTGGTATAGGTATTGT
EBER1	GGGTTTGGAGTTTTAGG	CACCCAACACTACACGTAAC	multiplex PCR 1, ext. oligo: aGTTAGTTGTAAGGTTAG
LMP1	TAGTGAGGTAAAGGTTGTG	CGACCCCTAACCCCTCTAAC	multiplex PCR 1, ext. oligo: ggGAGGTAAAGGTTGGGGTAAT
LMP2B	TAGAGCGATGAGTGGAGG	CCCTTTCCCTTACTCTTCC	multiplex PCR 1, ext. oligo: aGGGAAAGAGGGAGAACAGTG
Rp	GTTTAATGATGAGTGGGTAG	CCAAACCAATATTCAAAACAC	multiplex PCR 1, ext. oligo: GAGTGGGTAGAGGAGGTT
BARF0	GCGTATTTGCGGCGTTATAG	ACACCTTCATCACGAAACCC	multiplex PCR 2, ext. oligo: tgTTGGGTGGGGAAAGAGTT
BFRF1	AGTTGAGATCGAACAGCAGG	AATTCTCTTCCACGACGC	multiplex PCR 2, ext. oligo: TTTTTGGAGGGATAAAAGATT
BORF1	GGGGAGTTTAAAGGTTGTT	AACGTTCCAATACCTCGAC	multiplex PCR 2, ext. oligo: cccctTTTAAAGGTTGGGGTGG
OriLy	TCGTCGAGGACGCTGGGT	AAAACGAACCGACCCGACTC	multiplex PCR 2, ext. oligo: TGGGAGGGTGTATTGTT
Qp	GGGTGATTATTGAGGGAGTG	TCGCAAACGTAACCTCACC	multiplex PCR 2, ext. oligo: GTTTTATAGTATGTTGTTGTT
Wp	CGTATAATGGCGGATTTAGG	CTTATTCCCTTTCCCTC	multiplex PCR 2, ext. oligo: GGGTTTATGTTGGTTG
BSRF1	TGGTTGAAGYGGATYAGG	TCTCCCATCTCCATC	multiplex PCR 3, ext. oligo: cgtgTTGGTGGATAAAAGGTTGG
EBNA1	TYGYGTAGGTTTTAGG	TCACCATTAACACCCATCT	multiplex PCR 3, ext. oligo: TTTTTTATTGTTGAGGGAA
LF3	TGTTTTGGTTAGGTTAGG	CCCRGCRGAAARGAAACAA	multiplex PCR 3, ext. oligo: TTAGGATTAGTTGGAGTT
LMP2A/B	TYGGYGGAGAGAAAGTAAAG	TACCAACCTAATTCCCTCCC	multiplex PCR 3, ext. oligo: ggaaGAGAATAGGGTATAAAGTGT
BLLF1	GTGTTGTGGTGTGTTGTTAG	RGAAACATTAAACATTACTCTC	multiplex PCR 4, ext. oligo: ATGAGTGTGTTGGGGTT
EBER1	YGTGTTTTAGAGGTTGTTAG	ACCRGAAACTATACCRGAAAC	multiplex PCR 4, ext. oligo: tGTTAGTTGTTGGGGAGGAGA
BRLF1	AGGAAGAAAAGTGGGTTTGTAG	AARGRGARGAACCTAACAC	multiplex PCR 4, ext. oligo: GGGGAAATATGGGTTTAT
EBNA1	GGGTGATGAAAATAGAGGTTGG	AAATAACRGAACAAAACACRG	multiplex PCR 4, ext. oligo: GAAAATAGAGGTTGGATGTAG
LMP2A	GAGGGAAATTAGGTGGTAAATGG	TAACCAAACGTTCTCRAATCC	multiplex PCR 4, ext. oligo: ggAGGTTGGTAATGGGAGG
BZLF1	TGTTGTTAGTGTGTTTGTG	CCTCAACCTAAACAAATTCTAC	multiplex PCR 4, ext. oligo: AGTTGTTGGTTAGGTTAGTT
Cp	GTGGGAAAAATTATTATGTT	TTATTCTTCCCrCCAAC	multiplex PCR 4, ext. oligo: GGGAAAAAAATTGTTAGGTTAGT
BALF2	TAGYGTGTTGGTAGTGTAGTTT	TCTCCCTACCCATCTATATAC	multiplex PCR 5, ext. oligo: GGGGGTTTGGTAAAGTT
LMP1	AAAGTTGTTGGAGTTATGGTG	AACCCCTACTCCACAAACATC	multiplex PCR 5, ext. oligo: tGGGATGTATGTTGGTTTT
BMRF1	AGTTAAGGTTGATYGATTAAGGG	CRATAAAAACATCTACCTCC	multiplex PCR 5, ext. oligo: tTTTGGATTAGGAGGTTAGTT
BFLF1/2	TATTTGTTGTTGAAGATGGGGTAG	AAACTAAACCTTCCAACCCAC	multiplex PCR 5, ext. oligo: AGATGGTGTATAAAAGTGT
BHRF1	GAAGGTTGGATGGTGGATT	CCAACTAACCTCTAAATCCAA	multiplex PCR 5, ext. oligo: ccTGGTGGATTATAATAGGG
BNLF2a	GAGTATTATTAGGAGTAGTTAG	CTTCTACRAAAACCAACCTAAC	multiplex PCR 5, ext. oligo: gcGGGAGTAGTTAGTTGTTGA

Suppl. Table 3. *BGLF4* transcription start sites (TSS) determined via 5'RACE. Table shows cell line/sample name, EBV genome coordinate (RefSeq ID NC_007605.1) of detected TSS, and PCR primers used in 5'RACE reverse transcription (RT) and two nested PCRs. ¹forward primer: 5'RACE_Qo, ²: forward primer: 5'RACE_Qi


Sample	TSS (ChrEBV)	GSP-RT anchor primer	primer (PCR1) ¹	primer (PCR2) ²
Raji	N/A	GSP_RT1	GSP_1	GSP_3
Rael	111527	GSP_RT1	GSP_1	GSP_3
LCL EBV B95-8	111581	GSP_RT1	GSP_1	GSP_3
LCL EBV B95-8	111545	GSP_RT1	GSP_1	GSP_3
LCL EBV B95-8	111793	GSP_RT2	GSP2	GSP4
HEK293 EBV	111793	GSP_RT2	GSP2	GSP4
CNSL #1	111527	GSP_RT1	GSP_1	GSP_3
CNSL #1	111793	GSP_RT2	GSP2	GSP4
CNSL #2	111793	GSP_RT2	GSP2	GSP4
CNSL #3	111527	GSP_RT1	GSP_1	GSP_3
CNSL #4	111790	GSP_RT2	GSP2	GSP4
CNSL #4	111581	GSP_RT1	GSP_1	GSP_3
CNSL #4	111527	GSP_RT1	GSP_1	GSP_3
CNSL #5	111568	GSP_RT1	GSP_1	GSP_3
CNSL #5	111581	GSP_RT1	GSP_1	GSP_3




Suppl. Figure 2. EBV DNA methylation and gene expression in CNSL. (A-C) RNA expression (qRT-PCR) and (D-F) DNA methylation determined via EpiTYPER in peripheral PTLD and CNSL tissue biopsies for EBV *BXLF1* (A,D), *BZLF1* (B,E) and *LMP1* (C,F). (G) Heatmap depicting EBV DNA methylation from n=31 methylation sites determined with methylation iPLEX assay. Samples were arranged via unsupervised clustering and annotated based on sample cohort and EBV locus. DNA methylation is depicted from 0% methylated (white) to 100% methylated (red). (H,I) Average DNA methylation of human repetitive elements *LTR* (H) and *Alu* (I) determined via EpiTYPER in CNSL (n=12) and peripheral PTLD (n=24) cohorts. (J,K) correlation of *BGLF4* RNA expression and EBV DNA load in determined via qPCR tissue samples (J) or peripheral blood EBV DNA load from clinical chart review (K). (L) correlation of average EBV DNA methylation determined via iPLEX assay (n=31 EBV methylation sites) and EBV load in tissue biopsies determined via qPCR. Sample cohorts are annotated in red (CNSL) and blue (peripheral PTLD). R²: correlation coefficient. *p<0.05, t-test (D-F: Exact Wilcoxon-Mann-Whitney test)



Suppl. Figure 3. Site-specific methylation loss at EBV *BGLF4*. (A) Heatmap depicting EBV DNA methylation at the *BGLF4* upstream region determined via EpiTYPER assay. Samples were annotated based on sample cohort (green: cell lines, blue: peripheral PTLD, red: CNSL). EBV genome coordinates (EBV genome Refseq ID: NC_007605.1) are shown above, with DMR CpG 1, 2 and 3 annotated in orange. DNA methylation is depicted from 0% methylated (white) to 100% methylated (red). (B-D) DNA methylation for DMR CpGs 1 (B), 2 (C) and 3 (D) in cell lines (green), peripheral PTLDs (blue) and CNSL (red). Cohorts were separated based on pathology reports. DLBCL: Diffuse Large B-cell lymphoma, PBL: plasmablastic lymphoma, BL: Burkitt lymphoma. (E) ROC curve and sensitivity/specificity for n≥2 hypomethylated (<50% methylation) DMR CpGs as a marker of high *BGLF4* RNA expression (qRT-PCR, 4th quartile of combined CNSL/peripheral PTLD cohort). *p<0.05, **p<0.01, t-test.



Suppl. Figure 4. BGLF4 DMRs possess gene promoter activity. (A) Luciferase reporter assay of *BGLF4* upstream DNA elements in HEK293 or HEK293 M81 EBV cells. DNA sequences representing DMRs are marked in orange. EBV genomic coordinates, CpG islands (green) and EBV transcripts (blue) are indicated above. Bar graphs show mean \pm standard deviation of quadruplicate readouts. (B-E) Results from 5'RACE in n=4 cell line samples with detectable *BGLF4* RNA expression. Plots show DNA methylation across the *BGLF4* upstream region in each sample with detected TSS marked by vertical lines. Lower panels: CpG islands (green), EBV transcripts (blue), DMRs (orange) and Sequenced transcripts from 5'RACE (grey). (F,G) Violin plots depicting DNA methylation at single CpG sites closest to three TSS from 5'RACE (F) or average CpG methylation of all CpGs within 25 bp around TSS (G) with either detectable (total n=14) or undetectable (total n=13) transcript. TSS1: ChrEBV:111527, TSS2: ChrEBV:111581, TSS3: ChrEBV: 111793). Data are aggregate readouts from n=5 CNSL samples and n=4 EBV+ cell lines. *p<0.05, **p<0.01, ***p<0.0001, t-test (F,G: Exact Wilcoxon-Mann-Whitney test).



Suppl. Figure 5. Loss of TET function increases *BGLF4* promoter DNA methylation and lowers *BGLF4* expression. (A) Schematic of EBV latency establishment experiments. Parental M81 EBV HEK293 cells (blue) undergo lytic induction via lytic gene introduction (green). The collected viral particles are then used to infect HEK293 cells (either wild type, brown or TET2^{-/-}, red) and latency establishment occurs. (B) Western Immunoblot showing knockout of TET2 in CRISPR-Cas9 modified HEK293 cells and simultaneous knock-in of green fluorescent protein (GFP). Triplicate experiments are shown. (C) Heatmap depicting EBV DNA methylation from n=31 methylation sites determined via methylation iPLEX assay in parental M81 EBV HEK293 (blue), after lytic induction (green), EBV-infected HEK293 wild type control (brown) or TET2^{-/-} (red) cells. Samples were arranged via unsupervised clustering and annotated based on sample cohort and EBV locus. (D) Western Immunoblot showing stable lentiviral expression of IDH1 or mutated IDH1 R132H in HEK293 cells. Triplicate experiments are shown. (E) Methylation analysis of the *BGLF4* upstream locus using EpiTYPER assay in M81 EBV HEK293 cells (blue: parental, green: lytic induction, brown: EBV infected HEK293 wild type control, red: EBV infected HEK293 with lentiviral IDH1 R132H expression). EBV genomic coordinates and statistical significance for individual CpGs are annotated above. Lower panel: CpG islands (green), EBV transcripts (blue) and DMRs (orange). (F,G) *BGLF4* DNA methylation average from DMR3 CpGs (F, ChrEBV:111757, 111785, 111818) and *BGLF4* RNA expression (G) in parental (blue), wild-

type EBV infected control (brown) or IDH1 R132H-expressing EBV infected (red) HEK293 cells. (**H**) EBV DNA methylation average from n=31 EBV CpG sites determined via iPLEX assay in parental, lytic induced, re-infected or TET2-/ re-infected HEK293 cells. (**I**) Heatmap depicting EBV DNA methylation from n=31 methylation sites determined via methylation iPLEX assay in parental M81 EBV HEK293 (blue), lytic induction (green), EBV infected HEK293 wild type (brown) or EBV infected IDH1 R132H-expressing (red) cells. Samples were arranged via unsupervised clustering and annotated based on sample cohort and EBV locus. DNA methylation in heatmaps is depicted from 0% (white) to 100% methylated (red). All data show mean±standard deviation of biological triplicates. *p<0.05, ***p<0.001, ****p<0.0001, t-test (Suppl. Fig. 4E: Exact Wilcoxon-Mann-Whitney test.).